IP Library Granted Patent US 8,076,463
Granted Patent B2
US 8,076,463 · App. 13/007,208 · Granted Dec 13, 2011

Polymer-von Willebrand factor-conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,076,463
App. No.
13/007,208
Granted
Dec 13, 2011
Kind
B2
Abstract

The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.

Claims (13)

1. A method for forming a proteinaceous molecule comprising a von Willebrand Factor (VWF) molecule and a PEG moiety covalently bound to at least one carbohydrate residue on said VWF molecule, said proteinaceous molecule having the capability of binding at least one Factor VIII (FVIII) molecule, comprising: a) providing a VWF molecule selected from the group consisting of plasmatic VWF, recombinant VWF, and dimers and multimers thereof; b) oxidizing carbohydrate residues on said VWF molecule; c) contacting said carbohydrate residues with a PEG reagent containing a hydrazide group; and d) allowing said PEG hydrazide reagent to covalently bind to at least one carbohydrate residue on said VWF, thereby forming said proteinaceous molecule, wherein the in vivo half-life of said proteinaceous molecule is increased as compared to the in vivo half-life of a VWF molecule and the in vivo half-life of said FVIII molecule bound to said proteinaceous molecule is increased as compared to the in vivo half-life of a FVIII molecule not bound to said proteinaceous molecule.

2. The method of claim 1 wherein said oxidizing step of (b) is conducted using a chemical oxidizing agent.

3. The method of claim 2 wherein said chemical oxidizing agent is NaIO 4 .

4. The method of claim 1 wherein said oxidizing step of (b) is conducted using an enzymatic oxidizing agent.

5. The method of claim 4 wherein said enzymatic oxidizing agent is galactose oxidase.

6. The method of claim 1 wherein said PEG reagent is selected from the group consisting of linear alkoxy PEG, linear bifunctional PEG, branched PEG, multi-armed PEG, forked PEG, PEG attached to a polyol core, dendritic PEG, PEG with stable linkages, PEG with degradable linkages, and PEG with hydrolysable linkages.

7. The method of claim 6 wherein said PEG reagent has an internal structure selected from the group consisting of homopolymer, alternating copolymer, random copolymer, block copolymer, alternating tripolymer, random tripolymer, and block tripolymer.

8. The method of claim 1 whereby said PEG reagent is provided at a ratio of about 0.1 to about 200 mg PEG/mg VWF protein.

9. The method of claim 1 whereby said PEG reagent is provided at a ratio of about 1.0 to about 25 mg PEG/mg VWF protein.

10. A method for forming a proteinaceous construct molecule comprising a von Willebrand Factor (VWF) molecule and a polysialic acid (PSA) moiety covalently bound to at least one lysine residue on said VWF molecule, said proteinaceous molecule having the capability of binding at least one Factor VIII (FVIII) molecule, comprising: a) providing a VWF molecule selected from the group consisting of plasmatic VWF, recombinant VWF, and dimers and multimers thereof; b) contacting said VWF molecule with a PSA reagent containing an aldehyde; c) allowing said PSA reagent to covalently bind to at least one lysine residue on said VWF to form a Schiff base in solution; and d) contacting said solution with a reducing agent to form a secondary amino bond; thereby forming said proteinaceous molecule, wherein the in vivo half-life of said proteinaceous molecule is increased as compared to the in vivo half-life of a VWF molecule and the in vivo half-life of said FVIII molecule bound to said proteinaceous molecule is increased as compared to the in vivo half-life of a FVIII molecule not bound to said proteinaceous molecule.

11. The method of claim 10 wherein said reducing agent is NaCNBH 3 .

12. A method for forming a proteinaceous construct molecule comprising a von Willebrand Factor (VWF) molecule and a hyaluronic acid (HA) moiety covalently bound to at least one lysine residue on said VWF molecule, said proteinaceous molecule having the capability of binding at least one Factor VIII (FVIII) molecule, comprising: a) providing a VWF molecule selected from the group consisting of plasmatic VWF, recombinant VWF, and dimers and multimers thereof; b) contacting a solution of HA with an oxidizing agent to form activated HA; c) contacting said VWF molecule with said activated HA, thereby forming said proteinaceous molecule, wherein the in vivo half-life of said proteinaceous molecule is increased as compared to the in vivo half-life of a VWF molecule and the in vivo half-life of said FVIII molecule bound to said proteinaceous molecule is increased as compared to the in vivo half-life of a FVIII molecule not bound to said proteinaceous molecule.

13. The method of claim 1 wherein the step of oxidizing carbohydrate residues on said VWF molecule comprises contacting a carbohydrate residue on said VWF molecule with an oxidizing enzyme to form an oxidized carbohydrate moiety on said VWF.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036359 FRAME: 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 21, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036411/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE S.A.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036359/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036371/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2012
From: SCHEIFLINGER, FRIEDRICH; TURECEK, PETER; SIEKMANN, JUERGEN
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 028519/0866 →